F11 and venous thromboembolism: The phase II clinical trial data of antisense oligonucleotide FXI-ASO showed that subcutaneous injection of 300 mg FXI-ASO reduced FXI activity in patients undergoing total knee arthroplasty by 80%, APTT prolonged by 1.4 imes, and venous thromboembolism incidence rate was 4%, significantly lower than that in the enoxaparin group.